The high incidence of mortality in cancer patients is primarily related to drug resistance exhibited by the malignant cells. Through the SBIR project we aim to develop a novel technology that will monitor cancer drug resistance and provide timely screening of alternative drugs to facilitate the most effective course of treatment. This technology will be based on a highly accurate single cell sequencing technology that can interrogate both spatial and temporal resolution using nanogenomics. By integrating a nanopipetting technology that takes miniscule aliquot of single cell samples with NVIGEN highly sensitive magnetic nanoparticle enabled nucleic acid extraction, target enrichment and NGS sample preparation technology, longitudinal genomics of single cells can be measured with spatial and temporal resolution. Our technology enables single cell whole transcriptome analysis, and is orders of magnitude more sensitive than other methods. In phase I research, we will integrate the nanopipetting and nanoparticle single cell sequencing workflow, making it a useful tool for obtaining single cell sequencing information and assessing drug resistance in tissue samples with spatial resolution. In phase II, we will collaborate with a leading instrumentation and imaging devices company to automate the nanopipetting and nanoparticle library preparation for single cell sequencing with spatial resolution.